Novartis Entresto sales up 59% in Q1; guidance affirmed [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
Healthcare|On the MoveNovartis Entresto sales up 59% in Q1; guidance affirmedApr. 28, 2020 6:23 AM ETNovartis AG (NVS)Mamta MayaniNovartis (Q1 resultsRevenues: $12,283M (+10.6%); Innovative Medicines: $9,755M (+11.1%); Sandoz: $2,528M (+8.7%).Net Income: $2,173M (+16.3%); EPS: $0.96 (+18.5%); non-GAAP Net Income: $3,549M (+26.3%); non-GAAP EPS: $1.56 (+28.9%).CF Ops: $2,528M (+8.3%).Top sellers: Cosentyx: $930M (+18%); Gilenya: $772M (+1%); Entresto: $569M (+59%); Lucentis: $487M (-9%); Tasigna: $487M (+12%); Promacta/Revolade: $403M (+31%); Tafinlar + Mekinist: $366M (+23%); Sandostatin: $374M (-5%); Gleevec/Glivec: $329M (+7%); Jakavi: $318M (+23%); Xolair: $307M (+9%); Afinitor/Votubia: $296M (-21%); Ilaris: $213M (+41%); Exjade/Jadenu: $172M (-28%); Zolgensma: $170M; Kisqali: $161M (+77%); .2020 GuidanceExcluding COVID-19-related forward purchases, sales growth is estimated to be approx. 9% (cc).Shares are upPreviously:Novartis EPS beats by $0.20, beats on revenueSee all stocks
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NYSE:NVS) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
- JPM26: Vor Bio narrows focus to two-indication strategy [Yahoo! Finance]Yahoo! Finance
- Novartis CEO Dr. Vasant Narasimhan sits down with Jim Cramer [CNBC]CNBC
- Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- NVS's page on the SEC website